French Innovative Leukemia Organisation

This study is testing a new treatment schedule for older or frail adults with a type of blood cancer called chronic lymphocytic leukemia (CLL). All patients will first take the drug acalabrutinib for 18 months. Then, some will stop taking it to see if they can remain well without…

This trial is testing whether giving a targeted drug called venetoclax early can control high-risk chronic lymphocytic leukemia (CLL) in patients who have the disease but no major symptoms yet. The study involves 82 adults with specific high-risk features in their early-stage CLL…

This study is testing whether combining two drugs, ibrutinib and daratumumab, is safe and effective for people with a specific, hard-to-treat form of chronic lymphocytic leukemia (CLL). The trial is for adults whose CLL has come back or stopped responding to prior treatment and h…

This study aims to understand how doctors treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in real-world settings outside of controlled clinical trials. It will follow 1000 patients in France who need treatment, observing which therapies they receive,…